Glugacon-like peptide-2: Broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 307, Issue 3, 2014, Pages

  El Jamal, Noura ^a,b,d   Erdual, Edmone ^a,b   Neunlist, Michel ^e   Koriche, Dine ^c   Dubuquoy, Caroline ^a,d   Maggiotto, Francois ^a,b   Chevalier, Julien ^e   Berrebi, Dominique ^f,g,h,i   Dubuquoy, Laurent ^a,b   Boulanger, Eric ^b,j   Cortot, Antoine ^a,b,c   Desreumaux, Pierre ^a,b,c  

^a UNIVERSITÉ DE LILLE   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Intestinal Biotech Development   (France)

^e HÔTEL DIEU   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g INSERM   (France)

^h HÔPITAL ROBERT DEBRÉ   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j EA 2693   (France)

more..

Author keywords

Enteroendocrine cell; Glucagon like peptide; Inflammatory bowel disease

Indexed keywords

(1 33) GLUCAGON LIKE PEPTIDE 2; AGENTS USED IN INFLAMMATORY BOWEL DISEASE; BIOLOGICAL MARKER; DEXTRAN SULFATE; GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 RECEPTOR; HORMONE RECEPTOR; MESSENGER RNA; RECOMBINANT GLUCAGON; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER; CLINICAL ARTICLE; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; ENTERITIS; ENTEROENDOCRINE CELL; EXPERIMENTAL COLITIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY BOWEL DISEASE; INTESTINE INNERVATION; LIVER CELL; LIVER REGENERATION; MALE; MESENTERIC FAT; MESENTERY LYMPH NODE; MOLECULAR DYNAMICS; MOUSE; MYOFIBROBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; SPLEEN; TRINITROBENZENE SULFONIC ACID INDUCED COLITIS;

ENTEROENDOCRINE CELL; GLUCAGON-LIKE PEPTIDE; INFLAMMATORY BOWEL DISEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CACO-2 CELLS; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ENTEROENDOCRINE CELLS; GASTROINTESTINAL AGENTS; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 2; HEP G2 CELLS; HEPATECTOMY; HT29 CELLS; HUMANS; JURKAT CELLS; LIVER; LIVER REGENERATION; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; RATS; RECEPTORS, GLUCAGON; RECOMBINANT PROTEINS; RNA, MESSENGER; TIME FACTORS; TRINITROBENZENESULFONIC ACID;

EID: 84905227459     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00389.2012     Document Type: Article

References (50)

1. Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 98: 12497-12502, 2001.
2. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol Endocrinol Metab 277: E937-E947, 1999.
3. Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 16: 962-973, 2010.
4. Cao X, Flock G, Choi C, Irwin DM, Drucker DJ. Aberrant regulation of human intestinal proglucagon gene expression in the NCI-H716 cell line. Endocrinology 144: 2025-2033, 2003.
5. de Bruine AP, Dinjens WN, Pijls MM, van der Linden EP, Rousch MJ, Moerkerk PT, de Goeij AF, Bosman FT. NCI-H716 cells as a model for endocrine differentiation in colorectal cancer. Virchows Arch B Cell Pathol Incl Mol Pathol 62: 311-320, 1992.
6. de Heer J, Pedersen J, Orskov C, Holst JJ. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 50: 2135-2142, 2007.
7. de Heuvel E, Wallace L, Sharkey KA, Sigalet DL. Glucagon-like peptide 2 induces vasoactive intestinal polypeptide expression in enteric neurons via phosphatidylinositol 3-kinase-γ signaling. Am J Physiol Endocrinol Metab 303: E994-E1005, 2012.
8. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 93: 7911-7916, 1996.
9. Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol 76: 561-583, 2014.
10. Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol Gastrointest Liver Physiol 276: G79-G91, 1999.
11. Dube PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 293: E460-E465, 2007.
12. Dube PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 131: 589-605, 2006.
13. Dube PE, Rowland KJ, Brubaker PL. Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I. Endocrinology 149: 291-301, 2008.
14. Garrison AP, Dekaney CM, von Allmen DC, Lund PK, Henning SJ, Helmrath MA. Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion. Am J Physiol Gastrointest Liver Physiol 296: G643-G650, 2009.
15. Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold MJ, Holst JJ, Hadsell D, Nichols BL, Burrin DG. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 130: 150-164, 2006.
16. Guan X, Stoll B, Lu X, Tappenden KA, Holst JJ, Hartmann B, Burrin DG. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 125: 136-147, 2003.
17. Henriksen DB, Alexandersen P, Bjarnason NH, Vilsboll T, Hartmann B, Henriksen EE, Byrjalsen I, Krarup T, Holst JJ, Christiansen C. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 18: 2180-2189, 2003.
18. Henriksen DB, Alexandersen P, Byrjalsen I, Hartmann B, Bone HG, Christiansen C, Holst JJ. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 34: 140-147, 2004.
19. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, doseranging study in postmenopausal women with low BMD. Bone 45: 833-842, 2009.
20. Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 60: 902-914, 2011.
21. Jeppesen PB, Lund P, Gottschalck IB, Nielsen HB, Holst JJ, Mortensen J, Poulsen SS, Quistorff B, Mortensen PB. Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009: 616054, 2009.
22. Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, Gregory J, Tappenden KA, Holst J, Mortensen PB. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagonlike peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54: 1224-1231, 2005.
23. Kato Y, Yu D, Schwartz MZ. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg 34: 18-20; discussion 20-11, 1999.
24. Korner M, Rehmann R, Reubi JC. GLP-2 receptors in human disease: high expression in gastrointestinal stromal tumors and Crohn's disease. Mol Cell Endocrinol 364: 46-53, 2012.
25. Leen JL, Izzo A, Upadhyay C, Rowland KJ, Dube PE, Gu S, Heximer SP, Rhodes CJ, Storm DR, Lund PK, Brubaker PL. Mechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts. Endocrinology 152: 436-446, 2011.
26. Liu X, Murali SG, Holst JJ, Ney DM. Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats. Am J Physiol Regul Integr Comp Physiol 295: R1794-R1802, 2008.
27. Lovshin J, Estall J, Yusta B, Brown TJ, Drucker DJ. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem 276: 21489-21499, 2001.
28. Lovshin JA, Huang Q, Seaberg R, Brubaker PL, Drucker DJ. Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells. Endocrinology 145: 3495-3506, 2004.
29. Michalopoulos GK. Liver regeneration. J Cell Physiol 213: 286-300, 2007.
30. Mitchell C, Willenbring H. A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc 3: 1167-1170, 2008.
31. Moore BA, Peffer N, Pirone A, Bassiri A, Sague S, Palmer JM, Johnson DL, Nesspor T, Kliwinski C, Hornby PJ. GLP-2 receptor agonism ameliorates inflammation and gastrointestinal stasis in murine postoperative ileus. J Pharmacol Exp Ther 333: 574-583, 2010.
32. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 96: 1569-1573, 1999.
33. Nelson DW, Murali SG, Liu X, Koopmann MC, Holst JJ, Ney DM. Insulin-like growth factor I and glucagon-like peptide-2 responses to fasting followed by controlled or ad libitum refeeding in rats. Am J Physiol Regul Integr Comp Physiol 294: R1175-R1184, 2008.
34. Nian M, Drucker DJ, Irwin D. Divergent regulation of human and rat proglucagon gene promoters in vivo. Am J Physiol Gastrointest Liver Physiol 277: G829-G837, 1999.
35. Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 124: 105-112, 2005.
36. Pedersen NB, Hjollund KR, Johnsen AH, Orskov C, Rosenkilde MM, Hartmann B, Holst JJ. Porcine glucagon-like peptide-2: structure, signaling, metabolism and effects. Regul Pept 146: 310-320, 2008.
37. Powers AC, Philippe J, Hermann H, Habener JF. Sodium butyrate increases glucagon and insulin gene expression by recruiting immunocytochemically negative cells to produce hormone. Diabetes 37: 1405-1410, 1988.
38. Rowland KJ, Brubaker PL. The "cryptic" mechanism of action of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol 301: G1-G8, 2011.
39. Shi X, Zhou F, Li X, Chang B, Li D, Wang Y, Tong Q, Xu Y, Fukuda M, Zhao JJ, Li D, Burrin DG, Chan L, Guan X. Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons. Cell Metab 18: 86-98, 2013.
40. Sigalet DL, Wallace L, De Heuval E, Sharkey KA. The effects of glucagon-like peptide 2 on enteric neurons in intestinal inflammation. Neurogastroenterol Motil 22: 1318-e350, 2010.
41. Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji T, Tanaka H, Sharkey KA. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 293: G211-G221, 2007.
42. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6: 802-807, 2000.
43. Taub R. Liver regeneration: from myth to mechanism. Nat Rev Mol Cell Biol 5: 836-847, 2004.
44. Taylor-Edwards CC, Burrin DG, Matthews JC, McLeod KR, Holst JJ, Harmon DL. Expression of mRNA for proglucagon and glucagon-like peptide-2 (GLP-2) receptor in the ruminant gastrointestinal tract and the influence of energy intake. Domest Anim Endocrinol 39: 181-193, 2010.
45. 125I-GLP-2. Peptides 21: 1511-1517, 2000.
46. Trivedi S, Wiber SC, El-Zimaity HM, Brubaker PL. Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer. Am J Physiol Gastrointest Liver Physiol 302: G840-G849, 2012.
47. Tsai CH, Hill M, Drucker DJ. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am J Physiol Gastrointest Liver Physiol 272: G662-G668, 1997.
48. Velazquez E, Ruiz-Albusac JM, Blazquez E. Glucagon-like peptide-2 stimulates the proliferation of cultured rat astrocytes. Eur J Biochem 270: 3001-3009, 2003.
49. Yazbeck R, Howarth GS, Geier MS, Demuth HU, Abbott CA. Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. Front Biosci 13: 6850-6858, 2008.
50. Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, Demchyshyn L, Asa SL, Drucker DJ. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119: 744-755, 2000.